In a study reported in JAMA Otolaryngology Head & Neck Surgery, Neil Bhattacharyya, MD, of Brigham and Women’s Hospital and Harvard Medical School, and Elliot Abemayor, MD, PhD, of David Geffen School of Medicine at UCLA, analyzed recent patterns of hospitalization for head and neck...
In a study reported in Journal of Clinical Oncology, Greg Yothers, PhD, of the National Surgical Adjuvant Breast and Bowel Project (NSABP) Biostatistical Center and the University of Pittsburgh Graduate School of Public Health, and colleagues assessed performance of the 12-gene colon cancer...
Brentuximab vedotin (Adcetris) is active in patients with relapsed/refractory Hodgkin’s lymphoma. In a phase I study reported in The Lancet Oncology, Anas Younes, MD, of Memorial Sloan-Kettering Cancer Center (formerly of The University of Texas MD Anderson Cancer Center), and colleagues...
In a study reported in The Lancet Oncology, Jia-Xing Zhang, MD, of Sun Yat-sen University, and colleagues identified a six-microRNA (miRNA) signature that predicted risk of recurrence after surgery for stage II colon cancer and that may help to identify patients most likely to benefit from adjuvant ...
In a study reported in the Journal of Clinical Oncology, Dale Han, MD, of Moffitt Cancer Center, and colleagues in the Sentinel Lymph Node Working Group attempted to identify factors predictive of sentinel lymph node metastasis in thin melanomas. They found that Breslow thickness ≥ 0.75 mm, ...
In a study reported in the Journal of Clinical Oncology, Xin Huang, PhD, of the National Clinical Research Center of Cancer in Tianjin, and colleagues investigated whether STAT3 activation can identify patients with diffuse large B-cell lymphoma treated with R-CHOP (rituximab [Rituxan] plus...
In a randomized noninferiority trial (TARGIT-A) reported in The Lancet, Jayant S. Vaidya, PhD, and Michael Baum, MD, of University College London, and colleagues compared risk-adapted radiotherapy using single-dose targeted intraoperative radiotherapy vs fractionated external-beam radiotherapy in...
In the phase III Z1041 trial reported in The Lancet Oncology, Aman U. Buzdar, MD, of The University of Texas MD Anderson Cancer Center, and colleagues compared neoadjuvant therapy with FEC-75 (fluorouracil [5-FU], epirubicin, and cyclophosphamide) followed by paclitaxel plus trastuzumab (Herceptin) ...
In a study reported in the Journal of the National Cancer Institute, Susan Halabi, MD, of Duke University Medical Center, and colleagues developed and validated a prognostic model predicting prostate cancer survival in patients receiving second-line chemotherapy for castration-resistant...
In a study reported in Journal of the National Cancer Institute, Jiemin Ma, PhD, MHS, and colleagues from the American Cancer Society investigated trends in pancreatic cancer death rates in the United States between 1970 and 2009. They found that death rates have been increasing in white men and...
In a study reported in Journal of the National Cancer Institute, Mei-Yin C. Polley, PhD, of the National Cancer Institute, and colleagues assessed intralaboratory and interlaboratory variability in Ki67 scoring. They found high intralaboratory reproducibility but only moderate interlaboratory...
In a study reported in The New England Journal of Medicine, Carrie L. Williams, MB, BCh, of University College London, and colleagues analyzed risk for cancers among UK children born after assisted conception. They found no increased risk of cancer overall or for individual cancer types except...
In a phase III trial reported in The Lancet Oncology, Edward S. Kim, MD, of Levine Cancer Institute, Carolinas HealthCare System, and colleagues investigated whether the addition of cetuximab (Erbitux) to pemetrexed (Alimta) improved progression-free survival in patients with recurrent or...
In a study reported in JAMA Dermatology, Astrid Vredenborg, MD, of Leiden University Medical Center in the Netherlands, and colleagues evaluated whether acquired melanocytic nevi in childhood are an indicator of melanoma risk in children from families with familial melanoma. They found that number...
A single session of intraoperative radiotherapy with electrons permits delivery of a radiotherapy dose equivalent to that of conventional postoperative whole-breast irradiation. In the ELIOT trial reported in The Lancet Oncology, Umberto Veronesi, MD, of the European Institute of Oncology, and...
In a study reported in the Journal of Clinical Oncology, Boris Böll, MD, of University Hospital Cologne, and colleagues analyzed second-line treatment and survival in older patients with relapsed/refractory Hodgkin lymphoma in German Hodgkin Study Group first-line studies. Use of a...
Data suggest that Src kinase-mediated interactions between prostate cancer cells and osteoclasts might promote bone metastasis and that the Src kinase inhibitor dasatinib (Sprycel) might exhibit synergy with docetaxel in prostate cancer. In a phase III trial (READY) reported in The Lancet Oncology, ...
History of severe acne, which is a surrogate for high androgen activity, has been associated with increased risk of prostate cancer and recent data suggest that severe teenage acne is a risk factor for melanoma. In a study reported in the Journal of Clinical Oncology, Wen-Qing Li, PhD, of the...
In a study reported in the Journal of Clinical Oncology, Kevin R. Krill, PhD, and colleagues from St. Jude Children’s Research Hospital assessed neurocognitive function in adult survivors of childhood acute lymphoblastic leukemia (ALL). They found pervasive significant impairment across...
In a study reported in JAMA Surgery, Vincent Q. Trinh, BSc, of the University of Montreal Health Centre, and colleagues assessed trends in incidence and mortality of venous thromboembolism after major cancer surgery in the United States between 1999 and 2009. They found that venous thromboembolism...
In a study reported in JAMA Otolaryngology-Head & Neck Surgery, Okechukwu R. Linton, MD, MBA, of Indiana University School of Medicine, and colleagues assessed the prognostic significance of head and neck basaloid squamous cell carcinoma, which is considered a more aggressive form of squamous...
In a study reported in the Journal of Clinical Oncology, Oriana Yu, MD, of Jewish General Hospital in Montreal, and colleagues assessed the association of statin use with prostate cancer mortality and all-cause mortality in men with nonmetastatic prostate cancer. They found that postdiagnostic ...
The Group for Research in Adult Acute Lymphoblastic Leukemia (GRAALL) recently reported significantly better outcome in T-cell acute lymphoblastic leukemia (ALL) harboring NOTCH1 or FBXW7 (N/F) mutations, although relapse was still observed in one-third of patients with N/F-mutated T-cell ALL. In a ...
Available data suggest that risk of febrile neutropenia is greatest during the first two cycles of chemotherapy in patients with breast cancer. In a study reported in the Journal of Clinical Oncology, Maureen J. Aarts of Maastricht University Medical Centre in the Netherlands, and colleagues...
On October 31, 2013, Ariad Pharmaceuticals, the manufacturer of ponatinib, agreed to an FDA request to suspend marketing and sales of the drug due to the risk of life-threatening blood clots and severe narrowing of blood vessels. The FDA states that it will continue to evaluate ponatinib to further ...
In a study reported in The Lancet, Guglielmo Ronco, MD, of the Center for Cancer Epidemiology and Prevention, AO City of Health and Science, in Turin, Italy, and colleagues in the International HPV Screening Working Group performed a follow up of four randomized trials of human papillomavirus...
Recommended treatment for most stage I rectal cancers is total mesorectal excision. However, local excision is considered an alternative for T1 tumors that are < 30% of the bowel circumference, < 3 cm in size, mobile, well to moderately differentiated, and lack lymphovascular invasion in...
The strategy of autologous stem cell transplantation as consolidation in high-intermediate– or high-risk diffuse aggressive non-Hodgkin lymphoma (NHL) has not been specifically examined in the rituximab (Rituxan) era. In a phase III trial (Southwest Oncology Group 9704) reported in The New...
In a study reported in a research letter in JAMA Internal Medicine, Zehra B. Omer, BA, of Massachusetts General Hospital, and colleagues assessed how the description of ductal carcinoma in situ (DCIS) affected selection of treatment options. They found significant differences in treatment...
Because statins exhibit immunomodulatory and anti-inflammatory effects that may ameliorate graft-vs-host disease, they may be a safe strategy following allogeneic hematopoietic cell transplantation. In a phase II study reported in the Journal of Clinical Oncology, Mehdi Hamadani, MD, and colleagues ...
Propofol is increasingly being used for sedation in screening colonoscopies in low-risk patients. In the United States, propofol can be administered only by an anesthesiologist, which can raise the cost of the procedure by $600 to $2,000. In a study reported in a research letter in JAMA Internal...
A recent study by Darby and colleagues showed a significant linear increase in risk for major coronary events according to mean cardiac dose of radiation (7.4% per Gy) in patients receiving radiation therapy for breast cancer between 1958 and 2001. In an analysis reported in a research letter...
In a Canadian study reported in the Journal of the National Cancer Institute, Kerry S. Courneya, PhD, of the University of Alberta, and colleagues assessed the impact of different levels of physical exercise on physical functioning in women receiving adjuvant chemotherapy for breast cancer....
In a phase I trial reported in the Journal of Clinical Oncology, Jeffrey S. Weber, MD, of the H. Lee Moffitt Cancer Center and Research Institute, and colleagues assessed the effects of nivolumab—a human immunoglobulin G4-blocking antibody against the T-cell programmed death 1 checkpoint ...
In a phase III trial reported in The Lancet Oncology, Thomas E. Hutson, DO, PharmD, of Baylor Sammons Cancer Center and colleagues compared the second-generation VEGFR inhibitor axitinib (Inlyta) with sorafenib (Nexavar) as first-line treatment of metastatic renal cell carcinoma. There was no...
In a study reported in the Journal of Clinical Oncology, Julia Wade, PhD, of Bristol University, United Kingdom, and colleagues assessed the psychological impact of prostate biopsy. They found that postbiopsy symptoms can be associated with increased anxiety, independent of anxiety associated...
In a study reported in Journal of Clinical Oncology, Taxiarchis V. Kourelis, MD, and colleagues from the Mayo Clinic attempted to define a threshold of bone marrow plasma cell number that could serve to define light chain amyloidosis as light chain amyloidosis with multiple myeloma. They found that ...
In a phase I study reported in Journal of Clinical Oncology, Donald M. Cannon, MD, of University of Wisconsin School of Medicine and Public Health and Mountain States Tumor Institute, and colleagues attempted to identify the maximum tolerated dose of dose-escalated hypofractionated radiation...
In a study reported in The New England Journal of Medicine, Jean M. Mitchell, PhD, of Georgetown University, examined patterns of use of intensity-modulated radiation therapy to treat prostate cancer among urologists in private practice who have integrated intensity-modulated radiation therapy into ...
In a study reported in the Journal of Clinical Oncology, Patricia G. Moorman, PhD, of Duke University Medical Center, and colleagues evaluated risk of ovarian and breast cancer among oral contraceptive users with BRCA1/2 mutations. The study showed a significantly reduced risk of ovarian...
In a letter to The New England Journal of Medicine, Ségolène Hescot, MD, of Université Paris Descartes, and colleagues reported evidence of irreversible pancreatic atrophy in two patients after long-term sorafenib treatment. Both patients received cumulative doses of sorafenib...
Previously reported results of the phase III EORTC intergroup 40983 trial showed that perioperative chemotherapy with FOLFOX4 (leucovorin, fluorouracil [5-FU], and oxaliplatin) increased progression-free survival compared with surgery alone in patients with initially resectable liver metastases...
In a phase III trial reported in The New England Journal of Medicine, Daniel D. Von Hoff, MD, of Translational Genomics Research Institute in Phoenix, and colleagues assessed the addition of nanoparticle albumin-bound (nab)-paclitaxel (Abraxane) to gemcitabine in patients with previously untreated...
Axitinib plasma exposure may correlate with efficacy in metastatic renal cell carcinoma, according to population pharmacokinetic data. In a phase II study reported in The Lancet Oncology, Brian I. Rini, MD, of the Cleveland Clinic, and colleagues evaluated the effects of axitinib dose titration in...
In a study reported in the Journal of Clinical Oncology, I-Chan Huang, PhD, of University of Florida at Gainesville, and colleagues investigated the association between prevalence of symptoms and health-related quality of life in adult survivors of childhood cancer enrolled in the St. Jude...
In a phase III trial (EORTC [European Organisation for Research and Treatment of Cancer]/GIMEMA [Gruppo Italiano Malattie Ematologiche dell’Adulto] consortium AML-17 trial) reported in the Journal of Clinical Oncology, Sergio Amadori, MD, of Tor Vergata University Hospital in Rome, and...
In the RIGHT trial, reported in The Lancet Oncology, Yoon-Koo Kang, MD, of University of Ulsan College of Medicine in Seoul, and colleagues assessed the effects of imatinib (Gleevec) rechallenge in patients with metastatic or unresectable gastrointestinal stromal tumors (GIST) after objective...
Risk and risk factors for congestive heart failure in older breast cancer patients receiving trastuzumab have not been clearly defined. In a study reported in the Journal of Clinical Oncology, Mariana Chavez-MacGregor, MD, of The University of Texas MD Anderson Cancer Center, and colleagues...
In a randomized phase II trial reported in the Journal of Clinical Oncology by R. Wendel Naumann, MD, of Carolinas Medical Center in Charlotte, North Carolina, and colleagues, the addition of vintafolide to pegylated liposomal doxorubicin improved progression-free survival in women with...
Clinical trials have shown limited efficacy of anti–insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibodies, with the mechanisms of resistance to IGF-1R monoclonal antibody-based therapy remaining undefined. In preclinical studies reported in the Journal of the National...